A natural topical with superior efficacy to acyclovir — commercially available, Phase IIb ongoing
ErpeCream® demonstrates 97% lesion remission at 96 hours with a favorable safety profile (zero adverse events). Already registered in EU and UK. Phase IIb head-to-head vs acyclovir in progress with PPD (Thermo Fisher Scientific).
- 97% lesion remission at 96 hours vs 20% for topical acyclovir (Zovirax®)
- CPNP + UK.GOV registered — available for global distribution now
- Phase IIb: 80 patients, head-to-head vs acyclovir, CRO: PPD (Thermo Fisher Scientific)
Phase II open-label exploratory study, n=42. Non-head-to-head comparison. Comparators from published literature.
Why acyclovir is no longer sufficient
Acyclovir has been the standard of care for genital HSV since the 1980s. Yet resistance is rising, recurrence rates remain unacceptably high, and available topical formulations show only modest efficacy.
Growing Resistance
Increasing prevalence of nucleoside-analog resistance in HSV-2 — observed even in immunocompetent patients.
Piret & Boivin, Antiviral Research, 2011Frequent Recurrences
Frequent recurrences (6-10/year) with QoL impact. Recurrences ≥5/year predict worse psychological outcomes (p<0.01); depression in 29% of patients.
Gupta et al., 2025, Int J STD AIDSLow Topical Efficacy
Zovirax® topical (acyclovir 5%): cited as having 'no evidence of clinical benefit' for recurrences and 'no real activity over placebo' in clinical reviews.
Skyscape Clinical Consult; FDA Prescribing InfoUnmet Clinical Need
"Significant unmet needs"; "lack of preventive and curative therapies"; emerging resistance.
DelveInsight Market Report, 2025; Collins-Ogle & Herold, 2026Two registered products. Available today.
ErpeCream®
Oil-in-water nanoemulsion with 5 synergistic botanical actives. 97% efficacy in 96h. CPNP + UK.GOV registered.
- No systemic absorption · Zero adverse events in Phase II
- Distribution active: Europe, Gulf, Latam
ErpeLips™
Cold sores pocket treatment. 3ml compact format. 70% proven efficacy. Visible results in 24h.
- 100% natural patented formula · Neutral color (invisible application)
- Zero side effects · CPNP registered
- Targeting 3.7B HSV-1 patients globally (WHO)
Clinical validation in progress
Phase IIb head-to-head vs acyclovir with PPD (Thermo Fisher Scientific)
Fully budgeted Phase IIb/III program: 80 patients (ongoing) + 420 patients (planned Phase III)
Study Design
Randomized, double-blind, active-controlled multicenter study comparing ErpeCream® efficacy vs acyclovir 5% in adult patients with recurrent genital HSV-2.
Study Sites
Structured for Partnership
ACS Biomed actively seeks strategic partners for licensing, co-development, and regional commercialization across its pharmaceutical and medtech portfolio.